Insmed Inc (NASDAQ:INSM) Institutional Investors Sentiment Index Up in Q1 2018

July 27, 2018 - By Palma Niemeyer

Insmed Incorporated (NASDAQ:INSM) Logo

Sentiment for Insmed Inc (NASDAQ:INSM)

Insmed Inc (NASDAQ:INSM) institutional sentiment increased to 1.46 in 2018 Q1. Its up 0.46, from 1 in 2017Q4. The ratio improved, as 70 investment managers increased and opened new stock positions, while 48 cut down and sold holdings in Insmed Inc. The investment managers in our partner’s database now have: 77.55 million shares, up from 73.21 million shares in 2017Q4. Also, the number of investment managers holding Insmed Inc in their top 10 stock positions decreased from 3 to 1 for a decrease of 2. Sold All: 18 Reduced: 30 Increased: 47 New Position: 23.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.91 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

The stock increased 0.83% or $0.2 during the last trading session, reaching $24.91. About 387,978 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 61.09% since July 27, 2017 and is uptrending. It has outperformed by 48.52% the S&P500.

Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on August, 2. They expect $-1.01 EPS, down 40.28 % or $0.29 from last year’s $-0.72 per share. After $-0.86 actual EPS reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts 17.44 % negative EPS growth.

Foresite Capital Management Ii Llc holds 7.25% of its portfolio in Insmed Incorporated for 967,636 shares. Redmile Group Llc owns 2.17 million shares or 1.88% of their US portfolio. Moreover, Orbimed Advisors Llc has 0.82% invested in the company for 2.93 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.79% in the stock. Emerald Advisers Inc Pa, a Pennsylvania-based fund reported 726,946 shares.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $1.05 million activity.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Ratings analysis reveals 80% of Insmed’s analysts are positive. Out of 5 Wall Street analysts rating Insmed, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $32 while the high is $39.0. The stock’s average target of $35.20 is 41.31% above today’s ($24.91) share price. INSM was included in 5 notes of analysts from March 14, 2018. On Thursday, June 7 the stock rating was maintained by H.C. Wainwright with “Buy”. Leerink Swann maintained the shares of INSM in report on Wednesday, March 14 with “Buy” rating. The rating was upgraded by Credit Suisse on Monday, April 23 to “Outperform”.

More news for Insmed Incorporated (NASDAQ:INSM) were recently published by: Nasdaq.com, which released: “Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018” on July 26, 2018. Seekingalpha.com‘s article titled: “Liquidia Technologies files for $57.5M IPO” and published on June 29, 2018 is yet another important article.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.